Health Tidings Mergers & AcquisitionsChugai’s AID351 Anti-Dengue Antibody Licensed to GSK for Clinical Develop... Chugai’s AID351 Anti-Dengue Antibody Licensed to GSK for Clinical Develop... Read Post »
Health Tidings Mergers & AcquisitionsBioMarin to Acquire Alesta Therapeutics for $275 Million Upfront to Advance... BioMarin to Acquire Alesta Therapeutics for $275 Million Upfront to Advance... Read Post »
Health TidingsAVITA Medical Reports PermeaDerm Study Results Showing 70% Lower Treatment ... AVITA Medical Reports PermeaDerm Study Results Showing 70% Lower Treatment ... Read Post »
Health TidingsEvaxion Shifts Cancer Vaccine Focus to Glioblastoma With EVX-05 Following E... Evaxion Shifts Cancer Vaccine Focus to Glioblastoma With EVX-05 Following E... Read Post »
Health Tidings Mergers & AcquisitionsLEO Pharma Agrees to Acquire Dersimelagon, Expanding Late-Stage Rare Dermat... LEO Pharma Agrees to Acquire Dersimelagon, Expanding Late-Stage Rare Dermat... Read Post »
Health TidingsBlossomHill’s BH-30643 Gets FDA Fast Track Designation for EGFR C797S-Pos... BlossomHill’s BH-30643 Gets FDA Fast Track Designation for EGFR C797S-Pos... Read Post »
Health TidingsEli Lilly Joins $30 Million Series A to Advance Leal’s Schizophrenia and ... Eli Lilly Joins $30 Million Series A to Advance Leal’s Schizophrenia and ... Read Post »
GenericsBiocon Receives U.S. FDA Approval for YESINTEK® Single-Dose Prefilled Auto... Biocon Receives U.S. FDA Approval for YESINTEK® Single-Dose Prefilled Auto... Read Post »
Health TidingsFDA Grants Fast Track Designation to PIKTOR Plus Paclitaxel for Biomarker-S... FDA Grants Fast Track Designation to PIKTOR Plus Paclitaxel for Biomarker-S... Read Post »
Health TidingsFate Therapeutics Advances Fixed-Dose FT819 Into Phase 2 Lupus Nephritis Tr... Fate Therapeutics Advances Fixed-Dose FT819 Into Phase 2 Lupus Nephritis Tr... Read Post »
Health TidingsEyePoint Reports Mixed Phase 3 Results for DURAVYU in Wet AMD EyePoint Reports Mixed Phase 3 Results for DURAVYU in Wet AMD Read Post »
Health TidingsGalmed Reports 3–4-Fold Increase in Prostate Cancer Cell Death with Aramc... Galmed Reports 3–4-Fold Increase in Prostate Cancer Cell Death with Aramc... Read Post »
Health TidingsSpevatamig Receives FDA Fast Track Designation for Advanced and Metastatic ... Spevatamig Receives FDA Fast Track Designation for Advanced and Metastatic ... Read Post »
Health TidingsEnhertu Improves Progression-Free Survival in First-Line HER2-Mutant NSCLC ... Enhertu Improves Progression-Free Survival in First-Line HER2-Mutant NSCLC ... Read Post »
Health TidingsMHRA Approves Vimseltinib for Adults with Tenosynovial Giant Cell Tumour MHRA Approves Vimseltinib for Adults with Tenosynovial Giant Cell Tumour Read Post »
Health TidingsAbelZeta Secures IND Clearance for C-CAR039 in Relapsed or Refractory Large... AbelZeta Secures IND Clearance for C-CAR039 in Relapsed or Refractory Large... Read Post »
Health TidingsPfizer and Valneva Advances Lyme Disease Vaccine to EMA Review After Positi... Pfizer and Valneva Advances Lyme Disease Vaccine to EMA Review After Positi... Read Post »
Medical DevicesFDA Clears Galaxy Buds for Adults With Mild to Moderate Hearing Loss FDA Clears Galaxy Buds for Adults With Mild to Moderate Hearing Loss Read Post »
Health TidingsCaribou Reports Mature CAR-T Trials Results for Vispa-cel in LBCL and CB-01... Caribou Reports Mature CAR-T Trials Results for Vispa-cel in LBCL and CB-01... Read Post »
Health TidingsTHPharm Bets on Reverse Drug Development, Linking Drug Effects to New Disea... THPharm Bets on Reverse Drug Development, Linking Drug Effects to New Disea... Read Post »
Health TidingsLilly Escalates Legal Action Against U.S. Sellers of Unapproved Retatrutide Lilly Escalates Legal Action Against U.S. Sellers of Unapproved Retatrutide Read Post »
Health TidingsNatera and Kupando Collaborate on Phase 1 Trial of KUP-101 Using Latitude t... Natera and Kupando Collaborate on Phase 1 Trial of KUP-101 Using Latitude t... Read Post »
Health TidingsSagimet Receives FDA Clearance to Advance Phase 3 Denifanstat Acne Trial Sagimet Receives FDA Clearance to Advance Phase 3 Denifanstat Acne Trial Read Post »
Health TidingsRemepy Advances Hybridopa Toward Phase III After Positive Parkinson’s Dis... Remepy Advances Hybridopa Toward Phase III After Positive Parkinson’s Dis... Read Post »
Health TidingsAttralus’ Zamubafusp Alfa Gets FDA Fast Track for AL Amyloidosis Attralus’ Zamubafusp Alfa Gets FDA Fast Track for AL Amyloidosis Read Post »
Health TidingsCan-Fite Advances Namodenoson in Liver Cancer and Piclidenoson in Psoriasis Can-Fite Advances Namodenoson in Liver Cancer and Piclidenoson in Psoriasis Read Post »
Health TidingsDefinium’s DT120 Meets All Key Endpoints in Phase 3 Voyage Trial for Gene... Definium’s DT120 Meets All Key Endpoints in Phase 3 Voyage Trial for Gene... Read Post »
Health TidingsAnnexon Adds Month 24 Endpoint to Phase 3 ARCHER II Trial of Vonaprument in... Annexon Adds Month 24 Endpoint to Phase 3 ARCHER II Trial of Vonaprument in... Read Post »
Health TidingsBelite Bio’s Tinlarebant Wins FDA Priority Review for Stargardt Disease Belite Bio’s Tinlarebant Wins FDA Priority Review for Stargardt Disease Read Post »
Health TidingsPDS Biotech Shifts Focus to PDS0301, Discontinues PDS0101 Phase 3 Program PDS Biotech Shifts Focus to PDS0301, Discontinues PDS0101 Phase 3 Program Read Post »
Health TidingsFDA Accepts Lonafarnib NDA for Chronic Hepatitis D, Advancing Potential Fir... FDA Accepts Lonafarnib NDA for Chronic Hepatitis D, Advancing Potential Fir... Read Post »
Health Tidings Mergers & AcquisitionsSentynl Secures U.S. Option for Mereo’s Alvelestat Ahead of Phase 3 in AA... Sentynl Secures U.S. Option for Mereo’s Alvelestat Ahead of Phase 3 in AA... Read Post »
Health TidingsObinutuzumab β Reduces Relapse Risk by 93.1% in Phase 3 Trial of AQP4-IgG-... Obinutuzumab β Reduces Relapse Risk by 93.1% in Phase 3 Trial of AQP4-IgG-... Read Post »
Health TidingsFDA Grants Fast Track Designation to AC Immune’s ACI-7104 for Parkinson D... FDA Grants Fast Track Designation to AC Immune’s ACI-7104 for Parkinson D... Read Post »
Health TidingsVaderis Launches Phase 3 Trial of Engasertib in HHT After $152 Million Fund... Vaderis Launches Phase 3 Trial of Engasertib in HHT After $152 Million Fund... Read Post »
Health TidingsFDA Rejects ITM-11 NDA Over CMC and Facility Issues FDA Rejects ITM-11 NDA Over CMC and Facility Issues Read Post »
Health TidingsSoligenix Discontinues HyBryte Development After Phase 3 FLASH2 Trial Halte... Soligenix Discontinues HyBryte Development After Phase 3 FLASH2 Trial Halte... Read Post »
Health TidingsAquestive Reports Improved Human Factors and Comparable PK for Anaphylm Ahe... Aquestive Reports Improved Human Factors and Comparable PK for Anaphylm Ahe... Read Post »
Health TidingsSionna’s SION-719 Fails Phase 2a Sweat Chloride Endpoint in Cystic Fibros... Sionna’s SION-719 Fails Phase 2a Sweat Chloride Endpoint in Cystic Fibros... Read Post »
Health Tidings Mergers & AcquisitionsSobi enters strategic partnership with Innate Pharma to license lacutamab i... Sobi enters strategic partnership with Innate Pharma to license lacutamab i... Read Post »
Health TidingsNicox Announces NCX 470 NDA Submission in China by Partner Ocumension Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension Read Post »
Health Tidings Mergers & AcquisitionsBeOne, Revolution Medicines Expand RAS(ON) Cancer Collaboration in Asia BeOne, Revolution Medicines Expand RAS(ON) Cancer Collaboration in Asia Read Post »
Health TidingsRiboX Advances First-in-Class CAR-T Therapy Designed to Generate CAR-T Cell... RiboX Advances First-in-Class CAR-T Therapy Designed to Generate CAR-T Cell... Read Post »
Health TidingsBioInvent’s BI-1808 Wins FDA Fast Track Designation for Ovarian Cancer BioInvent’s BI-1808 Wins FDA Fast Track Designation for Ovarian Cancer Read Post »
Health TidingsVedanta Biosciences Secures $60 Million to Advance Phase 3 VE303 Trial for ... Vedanta Biosciences Secures $60 Million to Advance Phase 3 VE303 Trial for ... Read Post »
Health TidingsNeurocrine Biosciences Advances Triple Receptor Obesity Therapy NBIP-‘... Neurocrine Biosciences Advances Triple Receptor Obesity Therapy NBIP-‘... Read Post »
Health Tidings Mergers & AcquisitionsEvotec, Odyssey Partner to Advance AI-Driven Small Molecule Discovery for A... Evotec, Odyssey Partner to Advance AI-Driven Small Molecule Discovery for A... Read Post »
Health Tidings Mergers & AcquisitionsOno and Mediar Partner to Develop Novel Antibody Therapies for Fibrosis Ono and Mediar Partner to Develop Novel Antibody Therapies for Fibrosis Read Post »
Health TidingsDutch Court Grants Novo Nordisk Preliminary Injunction Against Compounded S... Dutch Court Grants Novo Nordisk Preliminary Injunction Against Compounded S... Read Post »
Health TidingsNICE Recommends Acalabrutinib-Based Regimens as New First-Line Options for ... NICE Recommends Acalabrutinib-Based Regimens as New First-Line Options for ... Read Post »
